|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-13.12/-10.33
|
企业价值
63.93M
|
资产负债 |
每股账面净值
18.37
|
现金流量 |
现金流量率
--
|
损益表 |
收益
7.00M
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/11 17:09 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261. |